Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Microbial cell wall and membrane structures are essential components that provide structural integrity, protection against osmotic pressure, and a selective barrier for nutrient transport in bacteria and fungi [1]. In bacteria, the cell wall is primarily composed of peptidoglycan, a complex polymer of sugars and amino acids, while the cytoplasmic membrane consists of a phospholipid bilayer [1, 2]. Fungal cell walls contain chitin and glucans, and their membranes are characterized by the presence of ergosterol [3]. These structures are critical therapeutic targets because they are often unique to microbes, allowing for selective toxicity with minimal impact on host cells [2, 4]. Drugs targeting these structures, such as beta-lactams, glycopeptides, and polymyxins, work by inhibiting synthesis or disrupting structural integrity, leading to cell lysis and death [4, 5]. Beta-lactams specifically inhibit the transpeptidation step of peptidoglycan synthesis, while glycopeptides like vancomycin bind to the D-Ala-D-Ala terminus of the cell wall precursor [2, 4]. Membrane-active agents like daptomycin and polymyxins disrupt the integrity of the cytoplasmic or outer membranes, causing leakage of cellular contents [4, 5]. Antifungal agents like polyenes bind to ergosterol, while azoles inhibit its synthesis, both leading to compromised membrane function [3]. The emergence of antimicrobial resistance, such as through the production of beta-lactamases or modification of target sites, remains a significant clinical challenge [5]. Despite these challenges, targeting the microbial envelope remains a cornerstone of infectious disease treatment due to the fundamental necessity of these structures for microbial survival [4]. References: [1] Silhavy, T. J., et al. (2010) Cold Spring Harb Perspect Biol. [2] Bugg, T. D., et al. (2011) Nat Rev Microbiol. [3] Gow, N. A. R., et al. (2017) Microbiol Spectr. [4] Kohanski, M. A., et al. (2010) Nat Rev Microbiol. [5] Lewis, K. (2013) Nat Rev Drug Discov.
Inhibition of peptidoglycan cross-linking, inhibition of cell wall precursor synthesis, disruption of membrane potential, pore formation in the cytoplasmic membrane, and inhibition of ergosterol synthesis or binding.
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Microbial cell wall and membrane structures.